Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

Purpose: Measurements of objective response rates are critical to evaluate new glioma therapies. The hallmark metabolic alteration in gliomas with mutant isocitrate dehydrogenase (IDH) is the overproduction of oncometabolite 2-hydroxyglutarate (2HG), which plays a key role in malignant transformatio...

Full description

Bibliographic Details
Main Authors: Andronesi, O. C. (Author), Loebel, F. (Author), Bogner, W. (Author), Marjanska, M. (Author), Iafrate, A. J. (Author), Dietrich, J. (Author), Batchelor, T. T. (Author), Gerstner, E. R. (Author), Kaelin, W. G. (Author), Chi, A. S. (Author), Rosen, B. R. (Author), Cahill, D. P. (Author), Vander Heiden, Matthew G. (Contributor)
Other Authors: Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Association for Cancer Research (AACR), 2018-07-11T20:44:11Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items